Home-based Diabetes-Modified Behavioral Activation Treatment for Low Income Seniors With T2DM
Part of paid clinical trials in Buffalo, New York.
- Sponsor
- State University of New York at Buffalo
- Study ID
- NCT04203147
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 65 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Supportive Therapy (Control) — BEHAVIORALDescription: 8-weekly sessions of in-home, supportive therapy and monthly booster sessions from months 3-12 via telephone.
- Home DM-BAT — BEHAVIORALDescription: 8-weekly sessions of in-home, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT) and monthly booster sessions from months 3-12 via telephone.
Study Details
The objective of this protocol is to evaluate the efficacy and cost-effectiveness of 8 sessions of in-home, telephone-delivered, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT) delivered by trained diabetes nurse educators among low income, ethnic minority seniors with poorly controlled T2DM. The aims of this randomized controlled efficacy trial are: Aim: To test the efficacy of Home DM-BAT on glycemic control (hemoglobin A1c). Hypothesis: Low income, minority seniors with poorly controlled T2DM randomized to Home DM-BAT will have significantly greater improvements in glycemic control (hemoglobin A1c) at 12 months of follow-up compared to the control group (in-home, telephone-delivered supportive therapy - ST).
Key Dates
- Start date
- Jan 3, 2020
- Status verified
- Feb 2026
- Primary completion
- Jun 30, 2025
- Completion
- Jan 1, 2026
Study Design
- Enrollment
- 200 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Home DM-BAT InterventionA trained nurse educator will deliver the manualized Home DM-BAT intervention. Subjects will receive 8-weekly sessions of behavioral activation and monthly booster sessions from months 3-12 via telephone.
- Active Comparator: Control Group (GHE+ST)Patients randomized to the control group will receive in-home 8-weekly sessions of combined general health education (GHE) and supportive therapy (ST) and monthly booster sessions from months 3-12 via telephone.
Primary Outcome Measure
Glycemic Control (HbA1c) [ Time Frame: HbA1c at 12 months post intervention follow-up ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| State University of New York at Buffalo | Buffalo | New York | 14203 | - |
Find similar trials in Buffalo, NY
Related Studies
- Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes PatientsPHASE1/PHASE2 · Not Yet Recruiting · ARKAY Therapeutics · Albany, New York
- Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes MellitusNot Yet Recruiting · Bionime Corporation · Guntersville, Alabama
- Novel Digital Patient-Reported Outcomes Tool for Diabetes ManagementRecruiting · NYU Langone Health · New York, New York
- Implementing an Effective Diabetes Intervention Among Low-Income ImmigrantsRecruiting · NYU Langone Health · New York, New York